News | Hypertension | December 27, 2018

Barbershop Intervention Continues to Lower Blood Pressure at One Year

Reductions in systolic blood pressure observed at 6 months in Cedars-Sinai study were sustained at 12 months

Barbershop Intervention Continues to Lower Blood Pressure at One Year

December 27, 2018 — African-American men participating in a blood pressure reduction program implemented in barbershops continued to have significant improvements in their blood pressure in a twelve-month follow-up study. The research was published in the American Heart Association journal Circulation.1

In the study led by Cedars-Sinai’s Smidt Heart Institute, 52 Los Angeles County barbershops were assigned to either a pharmacist-led intervention or an active control group. In the intervention group, barbers measured blood pressure and promoted follow-up with pharmacists who prescribed blood pressure medication under a collaborative practice agreement with study participants’ primary care providers. In the control group, barbers measured blood pressure and promoted follow-up only with primary care providers and lifestyle modification. At 6 months, the men in the intervention group had significant reductions in their blood pressure compared to those in the control group.

Read the article "Managing Blood Pressure in Barbershops Yields Substantial Improvements" 

After six months, the intervention group continued the program, but had fewer in-person pharmacist visits to test if the intervention effect could be sustained safely for one year while reducing pharmacist travel time to and from barbershops.

When the study began, participants had an average systolic blood pressure of 152.4 mm Hg in the intervention group and 154.6 mm Hg in the control group. Systolic blood pressure is the top number in a blood pressure reading and it measures the pressure the blood exerts against the arteries while the heart is pumping.

At 12 months, the average systolic blood pressure fell by 28.6 mm Hg (to 123.8 mm Hg) in the intervention group and by 7.2 mm Hg (to 147.4 mm Hg) in the control group. The average reduction was 20.8 mm Hg greater with the intervention. These results are indistinguishable from the previously reported 6-month data, which were published in the New England Journal of Medicine.2

The principal investigator for the study was the late Ronald G. Victor, M.D., associate director of the Smidt Heart Institute. In 2010, Victor became the first to prove, through randomized, controlled testing, that barbershop-based health programs could potentially save hundreds of lives annually by helping African American men lower their blood pressure.

Watch the VIDEO: Reducing Hypertension Among African-Americans

For more information: www.ahajournals.org/journal/circ

References

1. Victor R.G., Blyler C.A., Li N., et al. Sustainability of Blood Pressure Reduction in Black Barbershops. Circulation, Dec. 17, 2018. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.038165

2. Victor R.G., Lynch K., Li N., et al. A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops. New England Journal of Medicine, April 5, 2018. DOI: 10.1056/NEJMoa1717250


Related Content

News | Hypertension

Sept. 04, 2025 — CorVista Health has published a new case series in the Journal of the American College of Cardiology ...

Home September 09, 2025
Home
News | Hypertension

Sept. 5, 2025 — Idorsia Ltd has announced a first-of-its-kind initiative with the Stanford Hypertension Center and Duke ...

Home September 08, 2025
Home
News | Hypertension

Aug. 19, 2025 — Idorsia Ltd recently announced its novel dual endothelin receptor antagonist (ERA), Tryvio (aprocitentan ...

Home August 27, 2025
Home
News | Hypertension

May 19, 2025 — Gradient Denervation Technologies recently announced the company’s pulmonary denervation system has ...

Home May 20, 2025
Home
News | Hypertension

April 9, 2025 — Idorsia Ltd recently announced that the US Food & Drug Administration (FDA), after having released ...

Home April 09, 2025
Home
News | Hypertension

Mar. 10, 2025-- Corcept Therapeutics Inc., a commercial-stage company engaged in the discovery and development of ...

Home March 11, 2025
Home
News | Hypertension

Jan. 9, 2025 — Gender-based racism through microaggressions may be linked to higher blood pressure postpartum and beyond ...

Home January 14, 2025
Home
News | Hypertension

Jan. 8, 2025 — Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing medicines ...

Home January 08, 2025
Home
News | Hypertension

Dec. 11, 2024 — Older adults whose blood pressure fluctuates over time may be more likely to have problems with thinking ...

Home December 19, 2024
Home
News | Hypertension

June 28, 2024 — AstraZeneca has set out a new ambition for Healthy Heart Africa, its flagship health equity initiative ...

Home June 28, 2024
Home
Subscribe Now